Introduction
The prevalence of diabetes is increasing rapidly worldwide and is a major cause of morbidity and mortality (Guariquata et al., 2011) , with diabetic angiopathy having a particularly serious effect on quality of life and mortality of diabetic patients (Vinik and Flemmer, 2002) . Diabetic angiopathy can be classified into atherosclerotic macrovascular disease affecting the arteries that supply the heart, brain and lower extremities and diabetes-specific microvascular disease in the retina, glomerulus and vasa nervorum (Brownlee, 2001) . The dysfunction of vascular endothelial cells is considered to be a key initial step in diabetic angiopathy, and to affect the progression and severity of diabetes. Four main molecular mechanisms (increased polyol pathway flux, increased advanced glycation endproducts (AGEs) formation, activation of protein kinase C isoforms, and increased hexosamine pathway flux) appear to cause diabetic microvascular and macrovascular pathologies and all result from hyperglycemia (Brownlee, 2001) . Among these, we focused on AGEs, which affect vascular endothelial cells in diabetes, as AGEs are considered to be an important factor in the formation of diabetic vascular complications (Basta et al., 2004) . We also evaluated the effects of AGEs on ischemic stroke by administrating AGEs under hypoxia reperfusion conditions. While it is well known that diabetes enhances infarct volume and cerebral edema (Vannucci et al., 2001; Tureyen et al., 2011) , the detailed mechanisms by which diabetes exerts damage on brain microvascular endothelial cells remain unknown. We speculated that AGEs play an important role in the deterioration of the cerebral infarct in diabetes. AGEs are formed by non-enzymatic reactions between reducing sugars and free amino groups of proteins that undergo complex and irreversible molecular rearrangement. AGEs activate RhoA in endothelial cells, leading to increased hyperpermeability through actin polymerization (Hirose et al., 2010) , secondary prevention of cerebral infarction. Recently, cilostazol has been shown to be a more effective and safer alternative to aspirin for long-term prevention of the recurrence of ischemic stroke in patients with chronic ischemic stroke (Shinohara et al., 2010) . In addition, increasing evidence has shown that cilostazol also exerts a protective effect by promoting BBB integrity (Torii et al., 2007 , Horai et al., 2013 .
AGEs appear to be an important factor for the development of diabetic retinopathy and nephropathy, but the detailed mechanisms by which AGEs induce disruption of the BBB during diabetic cerebral microvascular disease remain unclear. A recent study has suggested that AGEs activate transforming growth factor (TGF)β to cause renal and vascular disease (Li et al., 2004) . Shimizu et al. (2011 Shimizu et al. ( , 2013 found that AGEs stimulated the release of TGF-β by pericytes. The TGF-β family is involved in many cellular processes, including cell growth, cell differentiation, migration, apoptosis, cellular homeostasis and other cellular functions, in both the developing embryo and the adult organism (Beck and Schachtrup, 2011) . However, excess TGF-β signaling is induced in the neurovascular unit upon central nervous system injury and disease with BBB rupture. Hara et al. (2009) reported that this increased TGF-β signaling causes cerebral arteriopathy in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL). CARASIL is characterized by ischemic, non-hypertensive, cerebral small vessel disease with associated alopecia and spondylosis, and magnetic resonance imaging demonstrated homogeneously confluent white matter changes and multiple lacunar infarctions in the basal ganglia and thalamus. Therefore, we suggested that TGF-β signaling is closely associated with BBB impairment induced by AGEs.
In the present study, we clarified the effects of AGEs on the BBB and the underlying mechanisms by analyzing tight junction (TJ) proteins and factors affecting endothelial cells.
Furthermore, we examined the effects of cilostazol on the BBB after exposure to AGEs under hypoxia reperfusion conditions.
Results

Transendothelial Electrical Resistance (TEER) in BBB Model Treated with AGEs
Transendothelial electrical resistance (TEER) in the BBB model was more than 150 Ω×cm 2 .
To analyze the potential harmful effects of AGEs on BBB integrity, we measured TEER under normoxia with or without AGEs. Treatment of AGEs (200 µg/mL, incubation at 37°C) under normoxia had no effect on TEER in the co-culture model. In contrast, treatment of AGEs under normoxia decreased the TEER when compared with BSA-control (200 µg/mL) at 24 h (TEER Our immunocytochemical study revealed continuous and linear staining for claudin-5 and ZO-1, a key protein composing TJs, marginally localized in the cell border between RBEC of BSA-control under normoxia ( Fig. 4A, E) . Microscopic observation revealed no significant differences in fluorescence intensity for claudin-5, but morphological distribution differed in RBEC treated with BSA under 3-h OGD/24-h reoxygenation (Fig. 4B ). Discontinuous localization of claudin-5 could be observed in RBEC treated with AGEs under 3-h OGD/24-h reoxygenation ( Fig. 4C ). Treatment with cilostazol increased the expression of claudin-5, leading to continuous, smooth patterns ( Fig. 3D ). In contrast, no significant changes were observed in the expression of ZO-1 after exposure to AGEs under 3-h OGD/24-h reoxygenation ( Fig. 4E-H) . Changes in the expression of claudin-5 and ZO-1 levels in in vitro BBB models treated with AGEs under 3-h OGD/24-h reoxygenation were investigated by Western blot analyses. While treatment with AGEs under 3-h OGD/24-h reoxygenation apparently decreased the expression of claudin-5 when compared with BSA under normoxia, treatment with cilostazol restored the expression of the claudin-5 ( Fig. 4I ). However, there were no differences in expression of ZO-1 in in vitro BBB models ( Fig. 4J ).
Involvement of TGF-β1 on AGE-induced BBB Dysfunction under OGD and Reoxygenation
In order to examine the functional association between AGEs and TGF-β1 levels, we measured the extracellular TGF-β1 concentration in BBB models treated with AGEs. As shown in Fig. 5A , treatment with AGEs were found to markedly increase TGF-β1 concentrations when compared with BSA under 3-h OGD/24-h reoxygenation (454.6 ± 7.2 pg/mL vs. 397.0 ± 4.9 pg/mL; P<0.01). On the other hand, cilostazol decreased TGF-β1 concentrations when compared with AGEs under 3-h OGD/24-h reoxygenation. These results suggest that production of TGF-β1 was increased by AGEs under 3-h OGD/24-h reoxygenation, and that cilostazol is able to regulate TGF-β1 production. Next, we used an inhibitor of TGF-β type I receptor to block the AGE-TGF-β interaction. A83-01 is a selective inhibitor of the TGF-β type I receptor ALK5, the Activin/Nodal receptor ALK4, and the nodal receptor ALK7. A83-01 elevated TEER, which was decreased by AGEs under 3-h OGD/24-h reoxygenation (TEER (% of normoxia BSA-control); AGEs + A83-01: 74.9 ± 7.7 vs. AGEs: 50.1 ± 2.9; P<0.01), while no significant differences were observed between BSA and BSA treated with A83-01 ( Fig. 5B ).
Effects of TGF-β1 on BBB Model
In order to examine the effects of TGF-β1 on the barrier function of the BBB, we administered TGF-β1 to the BBB model. Treatment of recombinant TGF-β1 (1 ng/mL, incubation at 37°C) significantly decreased TEER in a time-dependent manner when compared with controls, and cilostazol was able to inhibit the decrease in TEER induced by TGF-β1 ( Fig.   6 ).
Discussion
In the present study, we demonstrated that AGEs enhance ischemia-reperfusion injury, which mainly includes decreases in the expression of proteins comprising TJs through TGF-β1 signaling. Cilostazol reduced ischemia-reperfusion injury with AGEs by improving TJ proteins and inhibiting TGF-β1 signaling.
The BBB forms a neurovascular unit that protects the brain from circulating neurotoxic agents and inflammatory factors while maintaining nutrients and ions in the brain at levels suitable for brain function (Yan et al., 2012) . The BBB is composed of microvascular endothelial cells surrounded by pericytes and the astrocyte foot process. The integrity of endothelial cell-cell junctions is regulated by a series of adhesion molecules that make up TJs. Tsukita et al. (2001) revealed that claudin is an important adhesion molecule among the TJ proteins. Claudin-5 is particularly elevated in TJs in vascular endothelial cells and is associated with the maintenance of normal BBB function (Cardoso et al., 2010) . Zonula occludens protein-1 (ZO-1), ZO-2, and ZO-3 are exclusively concentrated at the cytoplasmic surface of TJs in the immediate vicinity of plasma membranes, and are bound to claudin (Itoh et al., 1999) .
Pericytes are important cellular constituents of the capillaries and post-capillary venules, having a close physical association with endothelial cells (Dore-Duffy, 2008). Armulik et al. (2010) demonstrated that pericytes in the BBB function in at least two ways: regulating BBB-specific gene expression patterns in endothelial cells, and inducing polarization of the astrocyte foot process surrounding central nervous system blood vessels. Astrocytes are glial cells whose foot process forms a lacework of fine lamellae closely apposed to the outer surface of endothelial cells. Perivascular astrocytes could be in partnership with endothelial cells, leading to a complex cell-cell exchange of chemical signals, inducing BBB features and modulating cellular physiology (Abbott, 2002) . The cross-talk among cells comprising the neurovascular unit is crucial for the formation and maintenance of the BBB. Accordingly, we used the triple co-culture BBB model ( Fig. 1 ) because this in vitro BBB model corresponds to the anatomical and physiological situation in the cerebral microvessels in vivo, as compared with the monolayer model of brain microvascular endothelial cells. Some reports have indicated that AGEs increase the permeability of the brain endothelial cell monolayer under non-ischemic conditions (Niiya et al., 2012 , Shimizu et al., 2013 . In agreement with these observations, the TEER value of our cultured RBEC monolayer decreased by treatment of AGEs (200 μg/mL) under non-ischemic conditions (data not shown). However, we could not confirm that AGEs affected the permeability of brain capillary endothelial cells in our triple co-culture model under normoxia. These observations suggest that cross-talk among cells comprising the BBB influences AGE/RAGE interaction via an unknown mechanism.
Diabetes is considered to be both a metabolic disease and a vascular disease because of its effects on macro-and microcirculation in numerous vascular beds, including cerebral vessels.
Generally, diabetes or chronic hyperglycemia contributes to proliferation of vascular smooth muscle cells, degeneration of endothelial cells and pericytes, thickening of the capillary basement membrane, and an increase in aggregation and adhesion of platelets to the endothelium (Ergul et al., 2009) . Accumulating evidence has indicated that AGEs increase at an accelerating rate in diabetes and in parallel with the severity of diabetic complications (Hirose et al., 2010) . AGEs are able to mediate diabetic complications by stimulating a number of mediators, including oxygen free radicals, cytokines, chemokines, adhesion molecules, TGF-β1 and connective tissue growth factor (Chung et al., 2010) . Vannucci et al. (2001) and Tureyen et al. (2011) have reported that a model of type-2 diabetes mouse that subjected to focal ischemia showed significantly higher mortality, bigger infarcts, increased cerebral edema and worsened neurological status as compared to nondiabetic animals. Diabetes exacerbates cerebral infarcts because hyperglycemia enhances superoxide anion radical generation in the blood, thereby increasing oxidative stress, early inflammation and endothelial injury after forebrain ischemia/reperfusion in rats (Tsuruta et al., 2010) , and increasing the permeability of endothelial cells comprising the BBB (Allen and Bayraktutan, 2009, Hawkins et al., 2007) . Starr et al. (2003) reported hyperpermeability of the BBB in type II diabetes on gadolinium magnetic resonance imaging. Our findings showed that AGEs further decrease TEER under OGD and reoxygenation conditions, as compared with normoxia, and these results support the notion that ischemia reperfusion injury in diabetes enhances the impairment of BBB integrity in vivo.
RAGE is present in minimal quantities in normal endothelial cells, but is upregulated in a positive-feedback manner when AGE ligands accumulate. These activities may induce inflammatory responses, leading to aggravation of diabetic vascular complications (Shimizu et al., 2011) . Our results also indicated the up-regulation of RAGE expression under OGD and reoxygenation. Furthermore, several studies have suggested that the expression of RAGE in endothelial cells is elevated under OGD and reoxygenation (Yan et al., 2008 , Zhai et al., 2008 .
Therefore, increased RAGE under ischemia-reperfusion is involved in the dysfunction of the BBB caused by AGEs. The enhanced interaction between AGEs and RAGE may accelerate inflammatory reactions, and worsen cerebral infarcts.
In order to elucidate the changes in TJ proteins after exposure to AGEs under OGD and reoxygenation, we examined the expression of claudin-5 and ZO-1 in RBEC in the BBB model. Claudin-5 is known to be the main structure responsible for the barrier properties of the BBB, and is thought to be closely related to the tightness of BBB integrity with a high TEER (Nitta et al., 2003; Furuse and Tsukita 2006; Koto et al., 2007; Tsukita et al., 2008) . The present immunocytochemical and Western blot analyses indicated that AGEs reduced the expression of claudin-5 in RBEC. In contrast to the expression of claudin-5, ZO-1 in the immunocytochemical and Western blot analysis did not differ after exposure to AGEs under OGD and reoxygenation.
Taken together with the previous report that the TEER was closely related to the amount of claudin-5 expressed as a TJ protein (Koto et al., 2007) , AGE-induced BBB impairment under OGD and reoxygenation is mainly associated with decreased expression of claudin-5.
Among the mediators stimulated by AGEs, TGF-β1 was related to disrupting the blood-nerve barrier and BBB in diabetic neuropathy (Shimizu et al., 2011 (Shimizu et al., , 2013 and the development of glomerulosclerosis in diabetic nephropathy (Chung et al., 2010) . In this study, we investigated whether TGF-β1 signaling contributes to the impairment of the BBB after exposure to AGEs.
We detected a significant increase in TGF-β1 release from RBEC subjected to OGD and reoxygenation. Furthermore, AGEs led to enhanced extracellular TGF-β1 concentrations under OGD and reoxygenation. In addition, the treatment of TGF-β1 significantly decreased TEER in a time-dependent manner when compared with controls in RBEC. TGF-β1 secretion from RBEC, which is elevated by AGEs under OGD and reoxygenation, works on neighboring endothelial cells as an autocrine factor. These data are in agreement with a recent study showing that TGF-β increased the permeability of brain capillary endothelial cells (Shen et al., 2011) . We observed that AGEs worked on RBEC to significantly decrease TEER, but this effect was inhibited by A83-01, a selective inhibitor of the TGF-β type I receptor ALK5, the Activin/Nodal receptor ALK4, and the nodal receptor ALK7. To the best of our knowledge, this is the first report regarding the relationship between AGEs and TGF-β1 signaling in the barrier integrity of the BBB under ischemic conditions. Our results suggested that the increase in TGF-β1 signaling was closely associated with impairment of the BBB after exposure to AGEs under OGD and reoxygenation. The inhibition of pathological response mediated by TGF-β1 signaling may represent a therapeutic target for diabetic cerebral vessel disease. However Dohgu et al. (2005) and Ronaldson et al. (2009) indicated that TGF-β has beneficial effects on BBB function under physiological and pathological pain conditions, respectively. Therefore, TGF-β appears to have different effects on BBB function, depending on physiological and pathological conditions. We clarified that cilostazol protected BBB integrity against AGE-induced impairment under OGD and reoxygenation. It is known that cAMP plays an important role in stabilizing the barrier properties of endothelial cells (Ishizaki et al., 2003; Deli et al., 2005; Noda et al., 2010), and Yamahishi et al., (1998) reported that AGEs decrease cAMP concentrations in endothelial cells. Cilostazol is a selective inhibitor of PDE3, and accordingly, it increases intracellular cAMP contents and activates PKA (Hashimoto 2006) . Horai et al. (2013) indicated that cilostazol elevated intracellular cAMP levels in RBEC and improved BBB integrity via the cAMP/PKA pathway. These findings suggest that cilostazol has potential as a protective drug against AGE-induced BBB dysfunction. In the present study, cilostazol enhanced the expression of claudin-5 and TEER values in RBEC treated with AGEs under OGD and reoxygenation.
Thus, cilostazol appears to protect the barrier function of the BBB, presumably through the cAMP/PKA pathway when AGEs reduce cAMP concentration in RBEC under OGD and reoxygenation.
Recent evidence has shown that diabetic rats treated with cilostazol effectively prevented the up-regulation of TGF-β1 expression in the kidney compared with untreated rats (Wang et al., 2009 ). We therefore hypothesized that cilostazol contributes to the suppression of TGF-β1 activation in the BBB. In the present study, our findings indicated that cilostazol decreases extracellular TGF-β1 concentrations after exposure to AGEs under OGD and reoxygenation.
These results suggest that cilostazol prevents AGE-mediated BBB dysfunction by reducing TGF-β1 production or activation. Furthermore, cilostazol improved BBB dysfunction induced by the treatment of recombinant TGF-β1 in the in vitro BBB model. As it has been reported that increased cAMP levels antagonize the inductive effects of TGF-β on fibroblasts (Togo et al., 2009; Schiller et al., 2010) , increases in intracellular cAMP levels by cilostazol may be involved in the protective effects of cilostazol.
In summary, AGEs reduced the barrier integrity of the in vitro BBB model under OGD and reoxygenation conditions, as compared with normoxia, and this effect may be due to the up-regulation of RAGE expression. AGEs enhanced ischemia-reperfusion injury, which decreased with the expression of claudin-5 containing TJs, and increased with TGF-β1 signaling.
Cilostazol appears to improve ischemia-reperfusion injury enhanced by AGEs through the inhibition of TJ protein disruptions by reducing the effects of TGF-β1 on brain capillary endothelial cells. The present study suggests that cilostazol is able to act as a BBB-protective drug for diabetic cerebral vessel disease. Nos. 80-23), and all protocols were approved by the Nagasaki University Animal Care Committee.
Experimental methods
Reagents and Animals
Cell cultures
Primary cultures of rat brain capillary endothelial cells (RBEC) were prepared from 3-week-old rats, as described previously (Deli et al., 1997; Nakagawa et al., 2007 Nakagawa et al., , 2009 ).
Meninges were carefully removed from the forebrain and gray matter was minced into small pieces of 1 mm 3 in ice-cold Dulbecco's modified Eagle's medium (DMEM), followed by dissociation with 25 up-and-down strokes using a 5-mL pipette in DMEM containing collagenage type 2 (1 mg/mL; Worthington Biochemical Corp., Lakewood, NJ, USA), 300 µL of DNase (15 µg/mL) and gentamycin (50 µg/mL), and digestion in a shaker for 1.5 h at 37°C.
Cell pellets were separated by centrifugation in 20% bovine serum albumin (BSA)-DMEM
(1,000 × g, 20 min). The microvessels obtained in the pellet were further digested with Pure cultures of rat cerebral pericytes were obtained by prolonged, 2-week culture of isolated brain microvessel fragments, which contain pericytes and endothelial cells. The same preparations yield primary RBEC after puromycin treatment. Pericyte survival and proliferation was favored by selective culture conditions using uncoated dishes, and DMEM supplemented with 10% fetal bovine serum and antibiotics. Culture medium was changed every 3 days.
Pericytes were characterized by their large size and branched morphology, positive immunostaining for α-smooth muscle actin, NG2 chondrotitin sulfate proteoglycan, and absence of von Willebrand factor and GFAP staining. Pericytes and astrocytes were frozen in cryo-medium CELLBANKER ® (Zenoaq, Koriyama, Japan), and were stored at -80°C until use.
Construction of in vitro BBB model
The day when endothelial cells were plated and models were established was defined as day four in vitro (day 4, Fig. 1 ). To construct an in vitro model of the BBB, pericytes (2.0 × 10 4 cells/cm 2 ) were cultured on the outside of the collagen-coated polycarbonate membrane (3.0-µm pore size; Corning Life Science, Tewksbury, MA, USA) of the Transwell inserts and astrocytes (1.0 × 10 5 cell/cm 2 ) were seeded on the bottom side of the Transwell. Cells were let to adhere firmly overnight, and endothelial cells (2.0 × 10 5 cells/cm 2 ) were seeded on the inside of the inserts placed in the well of the 12-well culture plates. From day 5, BBB models were maintained in RBEC medium II supplemented with 500 nM hydrocortisone (Hoheisel et al., 1998) . Under these conditions, in vitro BBB models were established within 3 days after setting of cells.
Normoxia conditions
Cells were cultured in RBEC medium II with bovine serum albumin (BSA) and AGE-BSA were added to the BBB model. Oxygen deprivation was generated using ANAEROPACK ® (Mitsubishi Gas Chemical Co., Inc., Tokyo, Japan). Reoxygenation was initiated by adding RBEC II medium after 3-h OGD. Cilostazol (10 μM) and AGEs (200 μg/mL) were added to the luminal (upper) compartment of the BBB model before and after 3-h OGD. After 24-h reoxygenation, transendothelial electrical resistance (TEER) was measured, as described below (Fig. 1) .
Measurement of TEER
Transendothelial electrical resistance, which reflects the flux of sodium ions through the cell layer, was measured using an EVOM resistance meter (World Precision Instruments, Sarasota, FL, USA). The extracellular matrix-treated Transwell inserts were placed in a 12-well plate containing culture medium and were then used to measure the background resistance. The resistance measurements of blank filters (background resistance) were subtracted from those filters with cells. Values are given as Ω × cm 2 , and data indicate the rate of change in TEER before and after treatment in comparison with normoxia BSA.
Immunocytochemical Detection of TJ Proteins
In order to observe changes in brain endothelial TJs, BBB cells were stained with primary antibody for zonular occludens-1 (ZO-1) and claudin-5, key proteins responsible for barrier functions through the BBB (Hiu et al., 2008 , Morofuji et al., 2010 . All primary antibodies were used at a dilution of 1 : 200. As secondary antibodies, Alexa Flour 488 conjugated donkey anti-mouse immunoglobulins (Invitrogen Corporation, Carlsbag, CA, USA) were used at a dilution of 1 : 1000. After 3-h hypoxia and 24-h reoxygenation with or without AGE treatment, cultures were washed in phosphate-buffered saline (PBS) and fixed in 3% paraformaldehyde in PBS for 10 min and permeabilized with 0.1% Trixon-X 100 for 10 min. Cells were blocked with 3% BSA and were incubated with primary antibodies anti-ZO-1 and anti-claudin-5 (Zymed Laboratories Inc., South San Francisco, CA, USA) overnight at 4°C. Cells were rinsed with PBS, and were incubated for 1 h at room temperature with secondary antibodies (Alexa Flour 488-conjugated donkey anti-mouse immunogloblins). Between incubations, cells were washed three times with PBS. Preparations were mounted in Gel Mount (Biomeda, Foster City, CA, USA) and staining was examined using a Zeiss LSM 5 Pascal Confocal laser scanning microscope (Carl Zeiss AG, Okerkochen, Germany).
Western Blot Analysis
Cells were harvested by scraping in CelLytic TM M cell lysis reagent supplemented with proteinase inhibitor cocktail (Sigma). Lysates were centrifuged at 15,000 × g for 5 min at 4°C, supernatants were collected, and protein concentrations were determined with BCA protein assay reagent (Pierce, Rockford, IL, USA). Samples were mixed with ×6 Laemmli sample buffer, and were heated at 95°C for 5 min. An equal amount of protein for each sample was 
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Fig. 6
Effects of transforming growth factor (TGF)-β1 on the transendothelial electrical resistance (TEER) in vitro blood-brain barrier (BBB) model. BBB models were exposed to TGF-β1 (1 ng/mL) under normoxia. Treatment of TGF-β1 significantly decreased TEER when compared with controls ( ** p < 0.01 vs. control). The decrease in TEER induced by TGF-β1 was improved in the presence of 10 µM cilostazol ( # p < 0.05, ## p < 0.01 TGF-β1 vs. TGF-β1 + cilostazol). TEER was measured at 3, 6, 9, 12 or 24 h, and values are expressed as a percentage of control values (mean ± SEM, n = 6). 
